Clinical trialPhase 2Suspended
IORT on Borderline Resectable Pancreatic Cancer
A Phase II Study of Primary Chemotherapy, Stereotactic Body Radiation Therapy, and Intraoperative Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma
- Outcome
- Stopped earlyLogistic and financial reasons (Business decision)
- Phase
- Phase 2
- Status
- Suspended
- Study type
- Interventional
- Start
- 1 October 2019
- Expected end
- 30 December 2027
- Enrollment
- 100 participants
- Sites
- 1
- Primary outcomes
- Disease-specific survival
- Sponsor
- Other
- Results posted
- No
- Last update
- 7 May 2024
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 5
- Builds on itA phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy… DOI 10.1186/s12885-021-07877-7↗
- BackgroundTotal Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancre… DOI 10.1001/jamaoncol.2018.0329↗
- BackgroundIntraoperative radiation therapy (IORT) in pancreatic cancer. DOI 10.1186/s13014-016-0753-0↗
- BackgroundThe role of intraoperative radiation therapy in patients with pancreatic cancer. DOI 10.1016/j.semradonc.2013.11.004↗
- BackgroundUpdated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer tre… DOI 10.1002/cncr.28329↗